MAGE-A1-derived peptide acetate

Cat. No.: HY-P10496A: FAQs
Data Sheet Handling Instructions Technical Support

MAGE-A1-derived peptide acetate is a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be recognized and activated by cytotoxic T lymphocytes (CTLs), thereby generating an immune response to tumor cells expressing MAGE-A1. This immune response can lead to the lysis and death of tumor cells. MAGE-A1-derived peptide acetate can be used in the study of tumor immunity.

For research use only. We do not sell to patients.

MAGE-A1-derived peptide acetate Chemical Structure

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of MAGE-A1-derived peptide acetate:

MAGE-A1-derived peptide Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Molecular Weight

1270.51

Formula

C₅₉H₁₀₃N₁₁O₁₉

Appearance

Solid

Sequence

Lys-Val-Leu-Glu-Tyr-Val-Ile-Lys-Val

Sequence Shortening

KVLEYVIKV

SMILES

O=C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N.CC(O)=O.CC(O)=O.CC(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Ottaviani S, et al. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells[J]. Cancer Immunology, Immunotherapy, 2005, 54: 1214-1220. [Content Brief]